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The advent of optogenetics has ushered in a new era in neuroscience where
spatiotemporal control of neurons is possible through light application. These tools used
to study neural circuits can also be used therapeutically to restore vision. In order to
recapitulate the broad spectral and light sensitivities along with high temporal sensitivity
found in human vision, researchers have identified and developed new optogenetic tools.
There are two major kinds of optogenetic effectors employed in vision restoration: ion
channels and G-protein coupled receptors (GPCRs). Ion channel based optogenetic
therapies require high intensity light that can be unsafe at lower wavelengths, so work
has been done to expand and red-shift the excitation spectra of these channels. Light
activatable GPCRs are much more sensitive to light than their ion channel counterparts
but are slower kinetically in terms of both activation and inactivation. This review article
examines the latest optogenetic ion channel and GPCR candidates for vision restoration
based on light and temporal sensitivity.
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INTRODUCTION
Shortly after the popularization of optogenetic tools in neuroscience began in the early 2000s
(Nagel et al., 2003, 2005; Boyden et al., 2005), researchers began evaluating their use in a novel
in vivo application: vision restoration. In America, over 1,000,000 people are currently considered
blind, with that number expected to double by 2030 (National Eye Institute, 2010). Most patients
suffering from retinal degenerative diseases, like retinitis pigmentosa and macular degeneration,
often first lose their light sensitive photoreceptors, the rods and cones, leaving the remaining
retinal tissue light insensitive (Figure 1). However, the surviving cells can retain functionality
and connections to the brain long after photosensitivity disappears. For decades researchers have
attempted to activate this remaining tissue with prosthetic electrical stimulation (Margalit et al.,
2002). With the advent of optogenetics, photosensitivity and vision can be restored at cellular
resolution.
The first successful attempt at bestowing light sensitivity to non-photoreceptor retinal
cells with optogenetic tools was in 2006 (Bi et al., 2006). In this pioneering work they
heterologously expressed a microbial opsin, channelrhodopsin-2 (ChR2) from Chlamydomonas
reinhardtii (Figure 2A), in thalamic projecting retinal ganglion cells (RGCs; Figure 1B) via
adeno associated virus (AAV) serotype 2. This groundbreaking article showed that endowing
surviving retinal cells with light sensitive proteins can restore light responses both retinally
and cortically. Furthermore, it was one of the first articles to use AAV as a retina delivery
vector and to demonstrate long term expression and safety. For over a decade researchers
have been improving upon this basic method of virally expressing optogenetic proteins
in surviving retinal cells, using new effectors to improve light and temporal sensitivity.
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FIGURE 1 | Retina schematic. (A) Diagram of a normal healthy retina. Light passes through the retina, entering through the retinal ganglion cell (RGC) layer to reach
the light sensitive photoreceptors, the rods and cones, in the outer retina. Visual information is sent from the photoreceptors to the bipolar cells where the ON/OFF
processing begins. Ganglion cells are the terminal retinal signal recipients and they relay onto neurons in the lateral geniculate nucleus in the thalamus. Panels (B,C)
depict the degenerate retina without photoreceptors. Panel (B) lists the optogenetic therapies that have been tested in ganglion cells (Bi et al., 2006; Lin et al., 2008;
Zhang et al., 2009; Caporale et al., 2011; Tomita et al., 2014; Sengupta et al., 2016; Berry et al., 2017), while (C) lists those tested in bipolar cells (Lagali et al., 2008;
Gaub et al., 2014, 2015; Macé et al., 2015; Scalabrino et al., 2015; van Wyk et al., 2015).
The ambitious aim to cure blindness optogenetically
has driven light sensitive protein development, benefiting
neuroscience as a whole with new effectors. Human vision
has broad spectral (400–700 nm) and light sensitivity (104
to 1016 photons cm−2 s−1) with high temporal resolution
(up to 60 Hz for long cone opsins; Kalloniatis and Luu,
1995). In order to restore sight, researchers have had to
step beyond ChR2 to find and engineer new optogenetics
that can better recapitulate human vision. In this review
article, we will compare the latest optogenetic ion-channel
and G-protein coupled receptor (GPCR) based technologies
in their effectiveness at restoring sight to blind retinas based
on the amount of light required for activation and temporal
sensitivity.
ION CHANNELS
The main advantage of optogenetic ion channel based therapies
is temporal sensitivity. Photoactivation allows ions to flow
through the channel activating or inhibiting the neural host.
Upon light stimulus removal, inactivation is quick. With
an opening and closing rate on the order of milliseconds,
optogenetic ion channels have the potential for successive
high frequency stimulation required for normal human vision
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FIGURE 2 | Therapeutic optogenetic effectors used to restore the visual response in degenerate retinas. (A) Structural diagrams of optogenetic microbial opsins,
mammalian opsins, and engineered GPCRs and ion-channels. The microbial opsins are all sodium permeable ion channels. The mammalian opsins, melanopsin and
rhodopsin, are GPCRs with six transmembrane domains containing the chromophore 11-cis retinal. The engineered GPCR Opto-metabotropic glutamate receptor 6
(mGluR6) is comprised of the transmembrane domains from melanopsin with the intracellular loops from mGluR6. SNAG-mGluR2 is mGluR2 with a N-terminal
SNAP-tag that tethers the PORTL BGAG. Upon light stimulation, the azobenzene in BGAG isomerizes allowing the distal glutamate to bind to the active site of
mGluR2. The engineered ion channel LiGluR is iGluR6 with a cysteine mutation that allows for the covalent binding of the photoswitch maleimide-azobenzene-
glutamate (MAG). Light isomerizes the azobenzene in MAG forcing the glutamate into the binding pocket. (B) Excitation spectra for optogenetic effectors used for
vision rescue (solid lines) and human cone opsins (dotted lines). (C) The minimum light required for activation for various optogenetic effectors when used for vision
rescue plotted against wavelength. (D) The τ decay constant plotted against wavelength for various optogenetic effectors. The excitation spectra, minimum light
requirements, and τ decay constants were collected from the following publications: Lin et al. (2008, 2009); Gaub et al. (2014, 2015); Tomita et al. (2014); van Wyk
et al. (2015); Pruneau et al. (2016); Sengupta et al. (2016); Berry et al. (2017).
(Figure 2D). However, light sensitivity is sacrificed for
temporal sensitivity, with most channels requiring at least 1015
photons cm−2 s−1 to activate their neural hosts (Figure 2C;
Bi et al., 2006; Sengupta et al., 2016). This amount of
light is dangerous at shorter wavelengths, like the 470 nm
that maximally activates ChR2 (International Commission
on Non-Ionizing Radiation Protection, 2013). Of growing
interest is ‘‘red-shifting’’ these ion channels to safer long
wavelengths.
One such ion channel that was successfully red-shifted is
the modified mammalian ion channel LiGluR (Figure 2A;
Volgraf et al., 2006). Based on the human ionotropic glutamate
receptor 6, LiGluR has a mutated cysteine residue that allows
Maleimide-Azobenzene-Glutamate (MAG), a photoswitchable
tethered ligand (PTL), to covalently bind to the outside of the ion
channel. Certain wavelengths of light isomerize the azobenzene
from trans to cis, forcing the distal glutamate into the protein’s
binding pocket opening the ion channel. The first generation
of MAG, MAG0, was bistable and used 380 nm light to open
and 500 nm to close. While this ultraviolet bistable channel
was able to restore the visual response (Caporale et al., 2011),
including the pupillary response, the amount and wavelengths
of light required are dangerous to humans. To circumvent these
problems, a second generation MAG, MAG460, was developed
(Kienzler et al., 2013). No longer bistable and activated at 460 nm
(Figure 2B), MAG460 was also able to restore the visual response
in both mice and dogs (Gaub et al., 2014). While the LiGluR-
MAG460 system requires a similar amount and spectrum of light
as ChR2 (Figures 2C,D), its modular design is advantageous.
Since LiGluR requires the PTL to be delivered in trans, patients
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would have the option of which one to have delivered and when,
which would be especially beneficial if other PTLs with different
activation spectrums are developed in the future.
Currently, in order to achieve activation using wavelengths
above 550 nm, different opsins are required. In 2008 the
Deisseroth group discovered the red-shifted ChR2 ortholog
VChR1 from Volvox carteri (Zhang et al., 2008). This cation
channel’s excitation spectrum is red shifted approximately 70 nm
when compared to ChR2, with a peak excitation at 535 nm and
a capacity to produce spiking at 589 nm. While this red-shifted
spectrum was promising, this channel does not express well due
to inefficient plasma membrane integration.
Various groups have tackled this expression problem by
generating chimeras with other microbial ion channels. Of
these chimeric microbial channels, ReaChR (Lin et al., 2013)
and mVChR1(Tomita et al., 2014) have demonstrated vision
restoration efficacy in rodents, and in the case of ReaChR,
primates (Figures 1B, 2A; Sengupta et al., 2016). ReaChR,
which used the N-terminus of ChiEF to facilitate membrane
trafficking, the transmembrane domain from VChR2 to increase
expression, and a L171I point mutation to reduce desensitization
above 600 nm, has a red-shifted activation spectrum with
a peak excitation ∼600 nm and is capable of generating
photocurrent at 630 nm (Figure 2B; Lin et al., 2013). In
mice this channel could produce spiking frequencies up to
30 Hz in ganglion cells and 22 Hz in macaque retinal
explants (Sengupta et al., 2016). Considering that film often
uses 24 frames per second, the temporal sensitivity of
ReaChR seems sufficient for vision rescue. While ReaChR
still requires light on the same order of magnitude as
ChR2 at 1015 photons cm−2 s−1 (Figure 2C), light at this
portion of the spectrum is safe up to 1017–18 photons cm−2
s−1 (International Commission on Non-Ionizing Radiation
Protection, 2013).
The other red-shifted chimeric channel, mVChR1, is
a fusion of VChR1 and the N-terminus Chlamydomonas
channelrhodopsin-1 (not to be confused with C1V1) and has the
largest activation spectrum of the ion channel based opsins tested
thus far, ranging from 468 nm to 640 nm (Figure 2B; Tomita
et al., 2014). The conductance of mVChR1 is not as efficient
as ChR2 and it also requires a similar amount of light to open
the channel. However, it is the only ion channel responsive to
light throughout the whole human visual spectrum, making it a
promising gene therapy candidate. To further improve spectral
sensitivity, the same group used both mVChR1 with ChR2 to
restore vision in blind mice (Sato et al., 2017). Unsurprisingly,
the use ofmultiple opsins generated greater light responses across
the spectrum than one opsin alone.
In 2014 another red-shifted microbial ion channel was
discovered in Chlamydomonas noctigama, termed ChrimsonR
(Figure 2A; Klapoetke et al., 2014). With a similar activation
spectrum and light requirements of ReaChR but with a faster
deactivation time constant (Figures 2B–D), ChrimsonR is
another strong vision restoration gene therapy candidate and is
currently in clinical trials (ClinicalTrials.gov, 2015).
Even though the red-shifted opsin variants use a safer
wavelength of light, they still require extremely bright light on
the order of 1015 photons cm−2 s−1 (Figure 2C). Since the light
is the direct effector of these ion channels, there is no way to
increase light sensitivity of the system other than increasing the
light sensitivity of the opsin itself. Currently, the best strategy to
increase light sensitivity is to use a light sensitive effector with the
capacity to amplify the light response, like GPCRs.
GPCRs
While there have been great improvements in spectral sensitivity
and conductance for light activated ion channels, they still pale in
comparison to the signal generated by optogenetic GPCRs. The
pay-off for this increased light sensitivity is a loss in temporal
sensitivity, with optical GPCRs lagging behind their ion channel
in terms of both activation and inactivation (Lin et al., 2008;
Cehajic-Kapetanovic et al., 2015; Gaub et al., 2015; Berry et al.,
2017; De Silva et al., 2017). However, the slower kinetics of
the optogenetic GPCR could be well tolerated due the loss of a
synaptic layer. Compared to wild type, the light signal was able to
reach V1 faster for the optogenetic ion channel gene therapies by
tens of milliseconds (Bi et al., 2006; Lagali et al., 2008; Caporale
et al., 2011; Macé et al., 2015; Sengupta et al., 2016). The loss of
the photoreceptors and their synapse means that there are fewer
cells the light signal has to pass between before reaching the brain
in these animals with restored vision. Due to this, the slowness of
the GPCRs can be partially compensated for by signal generation
in downstream cells.
The first GPCR to be adapted for vision restoration was the
light sensor for intrinsically photosensitive RGCs, melanopsin
(Figure 2A; Lin et al., 2008). Responsible for the pupillary light
response andmaintenance of circadian rhythms (Provencio et al.,
1998), melanopsin is a clear candidate for vision restoration
due to its established ability to generate light responses in
non-photoreceptor retinal cells. When delivered intravitreally
to the ganglion cell layer (Lin et al., 2008), or subretinally to
outer retinal cells (De Silva et al., 2017), melanopsin treated
retinas are three fold more light sensitive than any microbial
opsin, only requiring 1012 photons cm−2 s−1 to generate a
signal (Figure 2C). While melanopsin treated mice are able
to perform some basic light response behavior and show an
increased pupillary light response, the GPCR’s kinetics are
incredibly slow. It takes hundreds of milliseconds to several
seconds to activate melanopsin, and even longer for it to turn
off (Figure 2D; De Silva et al., 2017). This slow response time
is sufficient for basic perception (i.e., is it daytime or not), but
makes it a poor tool for the high acuity vision associated with
humans.
Another candidate for vision rescue is rhodopsin, the
exceedingly light sensitive GPCR found in rod photoreceptors
(Cehajic-Kapetanovic et al., 2015; Gaub et al., 2015). Rod
photoreceptors are capable of responding to a single photon
thanks to the phototransduction cascade. Light isomerizes
the chromophore 11-cis retinal into all-trans retinal, inducing
a conformational change in the GPCR which activates its
G-protein, transducin. The α-subunit of transducin dissociates
and activates phosphodiesterase (PDE), which lowers the
concentration of cGMP, closing cyclic nucleotide gated
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channels and hyperpolarizing the cell. When expressed in
non-photoreceptor cells, rhodopsin has a similar light sensitivity
to melanopsin of 1012 photons cm−2 s−1 (Figure 2C), but
importantly responds to light 10 times faster than melanopsin
(Figure 2D; Cehajic-Kapetanovic et al., 2015; Gaub et al., 2015).
However, when compared to rod photoreceptors, rhodopsin
activation in ganglion cells or bipolar cells is much slower. When
heterologously expressed, it is unlikely that the time to isomerize
11-cis or activate rhodopsin itself has changed, but rather the
lack of other phototransduction cascade proteins increases
cellular response times. Rod photoreceptors have specialized
discs which contain all the phototransduction cascade proteins
to promote efficient signaling. While other cells lack this specific
structure and phototransduction cascade, photoactivation
of other existing signaling cascades could improve temporal
sensitivity.
What is impressive is that the rhodopsin protein is
photosensitive at all. Many believed that rhodopsin outside
a photoreceptor would be unable to attain its 11-cis retinal
chromophore. 11-cis is tightly regulated being recycled from
all-trans in retinal pigment epithelium (RPE) and Müller cells,
which have developed specialized mechanisms to deliver the
incredibly photosensitive pigment to photoreceptors (Kiser et al.,
2014). While some teams have had to supply the 11-cis for
the multielectrode array (MEA) experiments, in vivo assays
demonstrated effective iterative activation of rhodopsin without
the use of exogenous chromophore (Cehajic-Kapetanovic
et al., 2015). Perhaps in the degenerate retina, the RPE and
Müller cells still produce 11-cis and can aberrantly deliver
it. Considering that photoreceptors contain approximately a
thousand discs each with thousands of rhodopsin molecules
(Nathans, 1992), the concentration of rhodopsin ectopically
expressed in ganglion cells or bipolar cells would pale in
comparison to wild type levels, perhaps low enough to
ensure chromophore delivery despite being non-target cells.
Furthermore, there might be alternative chromophore delivery
mechanisms. It was recently determined that melanopsin also
uses 11-cis (Walker et al., 2008), so whatever mechanism
delivers the 11-cis to melanopsin could potentially also deliver
it to rhodopsin when expressed in ganglion or bipolar
cells.
Recently, optically controlled GPCRs have been engineered
by multiple groups (Airan et al., 2009; Karunarathne et al.,
2013; Levitz et al., 2013; Broichhagen et al., 2015; van Wyk
et al., 2015; Morri et al., 2018). Unlike melanopsin or rhodopsin,
these GPCRs have been constructed or modified to become
light sensitive. One particularly interesting candidate, Opto-
metabotropic glutamate receptor 6 (mGluR6), is a chimeric
protein composed of the chromophore-adhering transmembrane
domains of melanopsin with the regulatory transmembrane
domains of mGluR6, the ON-bipolar specific GPCR (Figure 2A;
van Wyk et al., 2015). Opto-mGluR6 is the most light sensitive
construct tested so far, eliciting a light response at 5 × 1011
photons cm−2 at 473 nm (Figure 2C). In degenerate animals
expressing Opto-mGluR6 in their bipolar cells (Figure 1C), the
light responses generated signals in bipolar cells and ganglion
cells had similar timing to photoreceptor evoked light responses
in wild type animals. Expressing a photoactivable version of
the naturally occurring GPCR in the target cell type is an
enticing goal, however, the Opto-mGluR6 group had to resort to
transgenic animals to show any function or behavior. In order
for any of these therapies to be a viable option for people,
non-transgenic routes must be pursued.
DELIVERY METHODS
The goal of these ambitious projects is to cure blindness in
humans. While transgenic animals are an invaluable laboratory
tool, they are not applicable to humans. Viral transduction is
currently the best method to constitutively express heterologous
proteins in mammals. Other methods like electroporation have
been shown to successfully deliver transgenes in mice (de
Melo and Blackshaw, 2011), but the AAV method has been
demonstrated to be safe, effective and long lasting, as evidenced
by the recent FDA approval for the first vision restoration gene
therapy for LCA2 (Maguire et al., 2009; Simonelli et al., 2010;
Jacobson et al., 2012; FDA, 2017).
The current trend in many laboratories is to try and
recapitulate the ON/OFF light response by infecting ON-bipolar
cells with improved viral capsids and promoters (Figure 1C;
Doroudchi et al., 2011; Cronin et al., 2014; Gaub et al., 2014, 2015;
Cehajic-Kapetanovic et al., 2015;Macé et al., 2015; vanWyk et al.,
2015). The hypothesis is that infecting the furthest upstream
cells preserves the circuitry and processing resulting in a better
final signal sent to the brain. By using the mGluR6 promoter,
the ON-bipolar cell specific metabotropic glutamate receptor,
optogenetic gene expression is limited to these upstream cells.
ChR2 (Doroudchi et al., 2011; Cronin et al., 2014; Macé
et al., 2015), LiGluR (Gaub et al., 2014), rhodopsin (Cehajic-
Kapetanovic et al., 2015; Gaub et al., 2015) and Opto-mGluR6
(van Wyk et al., 2015) mediated light activation of bipolar cells
(Figure 1C) can produce ON and OFF responses in ganglion
cells and diverse responses in V1, unlike the simple ON response
produced by photosensitive ganglion cells.
While this is an admirable goal, bipolar cells are one of the
hardest cell types to infect in the retina (Dalkara et al., 2009).
Laboratories have engineered new and improved AAV variants
with unprecedented retinal penetration (Dalkara et al., 2013),
and even the best capsid variants do not efficiently transduce
bipolar cells. AAV never achieves complete infection and is
normally ‘‘patchy,’’ so complete restoration of a receptive field
looks unlikely. Furthermore, the mGluR6 promoters used to
restrict expression to the ON-bipolar cells may not work in many
retinal dystrophies due to dis- and downregulation of mGluR6
(van Wyk et al., 2017). mGluR6 is tonically activated by the
continuous release of glutamate by photoreceptors in the dark.
Upon photoreceptor cell death, mGluR6 is no longer stimulated
and the ON-bipolar cells undergo transcriptional changes that
limit mGluR6 expression and potentially other genes under that
promoter (Jones et al., 2016).
Instead of trying to restrict expression to bipolar cells, it might
be more advantageous to use ubiquitous promoters that would
allow expression in bipolar cells and other retinal cells to increase
light sensitivity. This way some greater processing is preserved
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allowing for the generation of ON and OFF light responses, while
generally increasing the light sensitivity of the retina as a whole.
MULTI-EFFECTOR THERAPY
Bipolar cells direct the ON and OFF pathways in healthy
tissue, but that does not mean that bipolar derived signal is
the only way to generate ON and OFF signals. There are a
variety of inhibitory optogenetic ion channels (Berndt et al.,
2014, 2016; Govorunova et al., 2015), pumps (Schobert and
Lanyi, 1982; Gradinaru et al., 2008; Chow et al., 2010) and
GPCRs (Levitz et al., 2013; Broichhagen et al., 2015) that
could emulate an ‘‘OFF’’ response. This was first demonstrated
by Zhang et al. (2009) by combining the inhibitory ion
pump HaloR with ChR2 to produce ON and OFF and
ON/OFF light responses. While HaloR requires 20 times more
light than ChR2, which already requires an unsafe amount
of light, this study importantly shows that the retina can
produce multiple types of light responses without bipolar cell
transduction.
Recently, Berry et al. (2017) improved upon Zhang’s
original work by using their engineered SNAG-mGluR2 and
LiGluR combination therapy. Similar to LiGluR, SNAG-mGluR2
is a modified version of the mGluR2 with a N-terminal
SNAP tag that allows stable conjugation of the azobenzene-
glutamate photoswitch by a selective benzylguanine-reactive
group (Figure 2A; Broichhagen et al., 2015). SNAG-mGluR2
is one of the fastest optogenetic GPCRs with kinetics on
the order of hundreds of milliseconds (Figure 2D), but it
unfortunately requires a similar amount of light as ChR2
(Figure 2C). The combination of the excitatory LiGluR ion
channel and inhibitory SNAG-mGluR2 GPCR generates diverse
light responses including ON, OFF and ON/OFF responses.
These diverse responses improved visual behavior in treated
mice compared to LiGluR or SNAG-mGluR2 alone. While this
combination therapy still requires bright light, it importantly
shows that multi-effector therapy has the potential to restore
complex and diverse cellular light responses similar to natural
vision.
CONCLUSIONS
The audacious goal of genetically restoring vision to the blind
is now possible. Newly discovered and developed optogenetics
have improved upon the original ChR2 studies. By red-shifting
ion channels, researchers have made safer alternatives with
broader spectrums. And new GPCRs are gaining speed to
allow for the temporal precision required for high acuity
vision. The new trend to use multiple effectors to generate
diverse responses should be expanded further. Humans use
three different cone opsins and one rod opsin to generate
vivid visual perception. With so many optogenetics with diverse
excitation spectra, combination therapies usingmultiple effectors
producing excitatory and inhibitory responses at different
wavelengths could generate the complex visual information
comparable to responses naturally derived in healthy tissue.With
new and innovative therapies constantly being developed, vision
restoration is within sight.
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